TY  - JOUR
A1  - Jeitler, Michael
A1  - Wottke, Till
A1  - Schumann, Dania Alexandra
A1  - Puerto Valencia, Laura M.
A1  - Michalsen, Andreas
A1  - Steckhan, Nico
A1  - Mittwede, Martin
A1  - Stapelfeldt, Elmar
A1  - Liebscher, Daniela Artemis Tahère
A1  - Cramer, Holger
A1  - Wischnewsky, Manfred
A1  - Murthy, Vijayendra
A1  - Keßler, Christian
T1  - Ayurvedic vs. conventional nutritional therapy including low-FODMAP diet for patients with irritable Bowel syndrome - a randomized controlled trial
T2  - Frontiers in medicine
N2  - Aims: To compare the effects of Ayurvedic and conventional nutritional therapy in patients with irritable bowel syndrome (IBS). Methods: Sixty-nine patients with IBS were randomized to Ayurvedic (n = 35) or conventional nutritional therapy according to the recommendations of the German Nutrition Society including the low-FODMAP diet (n = 34). Study visits took place at baseline and after 1, 3, and 6 months. The primary outcome was IBS symptom severity (IBS-SSS) after 3 months; secondary outcomes included stress (CPSS), anxiety and depression (HADS), well-being (WHO-5) and IBS-specific quality of life (IBS-QOL). A repeated measures general linear model (GLM) for intent-to-treat-analyses was applied in this explorative study. Results: After 3 months, estimated marginal means for IBS-SSS reductions were 123.8 [95% confidence interval (95% CI) = 92.8–154.9; p < 0.001] in the Ayurvedic and 72.7 (95% CI = 38.8–106.7; p < 0.001) in the conventional group. The IBS-SSS reduction was significantly higher in the Ayurveda group compared to the conventional therapy group (estimated marginal mean = 51.1; 95% CI = 3.8–98.5; p = 0.035) and clinically meaningful. Sixty-eight percentage of the variance in IBS-SSS reduction after 3 months can be explained by treatment, 6.5% by patients' expectations for their therapies and 23.4% by IBS-SSS at pre-intervention. Both therapies are equivalent in their contribution to the outcome variance. The higher the IBS-SSS score at pre-intervention and the larger the patients' expectations, the greater the IBS-SSS reduction. There were no significant group differences in any secondary outcome measures. No serious adverse events occurred in either group. Conclusion: Patients with IBS seem to benefit significantly from Ayurvedic or conventional nutritional therapy. The results warrant further studies with longer-term follow-ups and larger sample sizes. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03019861, identifier: NCT03019861.
KW  - nutrition - clinical
KW  - Traditional Indian Medicine
KW  - irritable bowel syndrome
KW  - Ayurveda
KW  - clinical trials
KW  - complementary medicine
KW  - integrative medicine
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62024
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-620240
SN  - 2296-858X
N1  - We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité - Universitätsmedizin Berlin.
VL  - 8
IS  - art. 622029
SP  - 1
EP  - 12
PB  - Frontiers Media
CY  - Lausanne
ER  -